Bruton's tyrosine kinase: Potential target in human multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 177-181

  Liu, Ying ^a   Dong, Ying ^b   Jiang, Qian Li ^c   Zhang, Bo ^d   Hu, An Mei ^e  

^a TSINGHUA UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF BIOPHYSICS   (China)

^e Shenzhen Baoan District People s Hospital   (China)

Author keywords

BTK; Multiple myeloma; Patients; Prognostic indicators

Indexed keywords

BRUTON TYROSINE KINASE; DEXAMETHASONE;

ADULT; AGED; ARTICLE; BONE MARROW CULTURE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

ADULT; AGED; BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN-TYROSINE KINASES; SEQUENCE ALIGNMENT;

EID: 84891349867     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.794458     Document Type: Article

References (21)

1. Birmann BM, Neuhouser ML, Rosner B, et al. Pre-diagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 2012; 120: 4929-4937.
2. Purushothaman A, Babitz SK, Sanderson RD. Heparanase enhances the insulin receptor signaling pathway to activate ERK in multiple myeloma. J. Biol Chem 2012; 287: 41288-41296.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J. Med 2005; 352: 2487-498.
4. Barbarulo A, Iansante V, Chaidos A, et al. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 2012 Oct 8. [Epub ahead of print]
5. Vlahovic G, Crawford J. A ctivation of tyrosine kinases in cancer. Oncologist 2003; 8: 531-538.
6. Bradshaw J. M. The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal 2010; 22: 1175-1184.
7. Holopainen T, Lopez-Alpuche V, Zheng W, et al. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res 2012; 72: 3512-3521.
8. Schmidt U, Boucheron N, Unger B, et al. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004; 134: 65-78.
9. Iyer AS, Morales JL, Huang W, et al. A bsence of Tec family kinases interleukin-2 inducible T cell kinase (Itk) and Bruton's tyrosine kinase (Btk) severely impairs Fc epsilonRI-dependent mast cell responses. J. Biol Chem 2011; 286: 9503-9513.
10. Tai YT, Anderson KC. Bruton's tyrosine kinase: Oncotarget in myeloma. Oncotarget 2012; 3: 913-914.
11. Bruton O C. Agammaglobulinemia. P ediatrics 1 952; 9: 7 22-7 27.
12. Bruton O C. Absence of serum gamma globulins. A m J. Dis Child 1952; 84: 632-636.
13. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
14. Smith CI, Baskin B, Humire-GreiffP, et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J. Immunol 1994; 152: 557-565.
15. Liu Y, Chen XQ, Liang HX, et al. Small compound 6-O-Angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS One 2011; 6: E21930.
16. Hu Z, Pan XF, Wu FQ, et al. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 2009; 4: E6257.
17. Yang Y, Shaffer A L III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
18. Vassilev A, Ozer Z, Navara C, et al. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J. Biol Chem 1999; 274: 1646-1656.
19. Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinasedependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J. Biol Chem 1999; 274: 10983-10989.
20. Satterthwaite AB, Li Z, Witte ON. Btk function in B cell development and response. Immunology 1998; 10: 309-316.
21. Uckun FM, Sudbeck EA, Mao C, et al. Structure-based design of novel anticancer agents 1. Curr Cancer Drug Targets 2001; 1: 59-71.